sections

NAFDAC Issues Advisory on Unregistered Novartis Prescription Medicines Imported via Murtala Mohammed Airport


NAFDAC Issues Advisory on Unregistered Novartis Prescription Medicines Imported via Murtala Mohammed Airport

The National Agency for Food and Drugs Administration and Control (NAFDAC) has issued a warning about the increase in parallel importation of certain Novartis Prescription-Only-Medicines (POM) brands, leading to a surge in the seizure of unregistered Novartis medicines at the Murtala Mohammed International Airport in Lagos during August and September 2023.

These unregistered medicines, duplicates of NAFDAC-registered Novartis brands, were discovered at a pharmacy in Yenagoa, Bayelsa State. Further investigation revealed that these products were sourced from various pharmacies in Turkey and amalgamated for export to Nigeria.

The intercepted products include Parlodel Tablets, Exforge HCT Tablets, Glucophage tablets, Tegretol CR tablets, and packaging materials designed for distribution in Turkey.

The illegal importation and sale of these medicines pose a serious threat to public health, bypassing legal importation processes and undermining product safety, quality, and efficacy assurances. In response, NAFDAC has increased surveillance measures at ports and across states to prevent the importation, distribution, and sale of unregistered pharmaceuticals.

NAFDAC advises importers, distributors, retailers, healthcare practitioners, and patients to exercise caution and vigilance throughout the supply chain, urging them to source medical products from authorized suppliers with a thorough assessment of authenticity.

Additionally, healthcare practitioners and consumers are encouraged to promptly report any suspicions of adverse drug reactions or the presence of substandard and counterfeit medicines.

Reports can be submitted to the nearest NAFDAC office, NAFDAC’s toll-free hotline at 0800-162-3322, or via email at sf.alert@nafdac.gov.ng.

Healthcare professionals and patients are also urged to report any adverse events or side effects related to the use of medicinal products. Reports can be submitted to the nearest NAFDAC office or through NAFDAC’s E-reporting platforms available on their website (www.nafdac.gov.ng) or via the Med-safety application, downloadable on both Android and IOS platforms. Alternatively, reports can be sent via email to pharmacovigilance@nafdac.gov.ng.

Differences between registered brand and unregistered brand of GalvusMet


0 Comments

Your email address will not be published. Required fields are marked *